文献速递心力衰竭与心肌病

索塔西普治疗射血分数保留心衰合并混合性肺动脉高压的2期研究

Sotatercept for Combined Post- and Precapillary Pulmonary Hypertension Associated With Heart Failure: Results From the Phase 2, Randomized, Placebo-Controlled CADENCE Study.
PubMed 文献 · Circulation · 2026-03-29

CADENCE研究为多中心、随机、安慰剂对照2期试验,纳入射血分数保留心衰合并混合性毛细血管后及毛细血管前肺动脉高压成人患者,比较索塔西普0.3 mg/kg、0.7 mg/kg与安慰剂每3周给药。结果显示索塔西普可降低肺血管阻力和平均肺动脉压,提示抑制激活素信号通路可改善此类患者肺血管及心脏血流动力学。

要点

  • 索塔西普0.3 mg/kg组24周肺血管阻力较安慰剂显著下降。
  • 两个剂量组均观察到平均肺动脉压降低。
  • 索塔西普最常见不良事件为血红蛋白升高和腹泻。

核心结论

  • 在射血分数保留心衰合并混合性毛细血管后及毛细血管前肺动脉高压患者中,索塔西普抑制激活素信号通路可改善肺血管和心脏血流动力学,提供概念验证证据。

研究设计与样本

  • 多中心、随机、安慰剂对照2期试验,成人患者按1:1:1随机分配至索塔西普0.3 mg/kg组、0.7 mg/kg组或安慰剂组,每3周给药一次。
  • 主要终点为第24周肺血管阻力相对基线的变化,采用Hodges-Lehmann位移估计描述安慰剂校正后的变化。
  • 共164例患者随机化,其中索塔西普0.3 mg/kg组54例、0.7 mg/kg组55例、安慰剂组55例。

主要发现

  • 基线肺血管阻力中位数为5.2 Wood单位(四分位距4.0-6.9)。
  • 第24周肺血管阻力相对基线的中位变化为索塔西普0.3 mg/kg组-0.67 Wood单位、0.7 mg/kg组-0.33 Wood单位、安慰剂组0.26 Wood单位。
  • 肺血管阻力的Hodges-Lehmann位移估计为0.3 mg/kg组-1.02 Wood单位(95%CI -1.81至-0.23,P=0.004),0.7 mg/kg组-0.75 Wood单位(95%CI -1.52至0.03,P=0.024)。
  • 平均肺动脉压降幅为0.3 mg/kg组-9.19 mm Hg(95%CI -13.00至-5.38),0.7 mg/kg组-9.22 mm Hg(95%CI -12.97至-5.46)。
  • 肺动脉楔压变化为0.3 mg/kg组-3.04 mm Hg(95%CI -5.77至-0.32),0.7 mg/kg组-2.53 mm Hg(95%CI -5.33至0.28)。

关键数值与推荐

  • 6分钟步行距离变化为0.3 mg/kg组20.3 m(95%CI 1.5至39.1),0.7 mg/kg组5.8 m(95%CI -17.3至28.9)。
  • 索塔西普两个剂量组最常见不良事件为血红蛋白升高和腹泻。

临床怎么用

  • 索塔西普有潜力成为射血分数保留心衰合并混合性肺动脉高压的靶向治疗选择,但需等待后续研究确认。
  • 用药期间需关注血红蛋白升高和腹泻等不良事件。

局限性

  • 本研究为2期试验,样本量有限,结果需在更大样本和更长期的研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combined post- and precapillary pulmonary hypertension in heart failure with preserved ejection fraction involves remodeling in both the heart and pulmonary vasculature. Despite significant mortality, there are no proven therapies. METHODS: In this multicenter, randomized, placebo-controlled, phase 2 trial, adults received sotatercept (0.3 or 0.7 mg/kg) or placebo every 3 weeks. The primary end point was change in pulmonary vascular resistance at week 24. Hodges-Lehmann shift estimates described placebo-adjusted changes. RESULTS: A total of 164 patients were randomized 54:55:55 to sotatercept 0.3 mg/kg, 0.7 mg/kg, and placebo, and baseline median pulmonary vascular resistance was 5.2 (interquartile range, 4.0-6.9) Wood units. The median change from baseline in pulmonary vascular resistance at week 24 was -0.67 Wood units in the sotatercept 0.3 mg/kg group, -0.33 Wood units in the sotatercept 0.7 mg/kg group, and 0.26 Wood units in the placebo group. The Hodges-Lehmann shift estimates in pulmonary vascular resistance were -1.02 Wood units (95% CI, -1.81 to -0.23; P=0.004) for 0.3 mg/kg and -0.75 Wood units (95% CI, -1.52 to 0.03; P=0.024) for 0.7 mg/kg sotatercept. Reductions were observed in mean pulmonary arterial pressure (0.3 and 0.7 mg/kg: -9.19 mm Hg [95% CI, -13.00 to -5.38] and -9.22 [95% CI, -12.97 to -5.46]) and pulmonary arterial wedge pressure (0.3 and 0.7 mg/kg: -3.04 mm Hg [95% CI, -5.77 to -0.32] and -2.53 [95% CI, -5.33 to 0.28]). Changes in 6-minute walk distance were 20.3 m (95% CI, 1.5-39.1) for 0.3 mg/kg and 5.8 m (95% CI, -17.3 to 28.9) for 0.7 mg/kg sotatercept. The most common adverse events with sotatercept (both groups) were increased hemoglobin and diarrhea. CONCLUSIONS: These findings provide proof of concept for improved pulmonary vascular and cardiac hemodynamics after activin signaling inhibition with sotatercept in patients with combined post- and precapillary pulmonary hypertension in heart failure with preserved ejection fraction. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04945460.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Gomberg-Maitland, Tedford, Langleben, et al. Sotatercept for Combined Post- and Precapillary Pulmonary Hypertension Associated With Heart Failure: Results From the Phase 2, Randomized, Placebo-Controlled CADENCE Study. Circulation. 2026. PMID: 41904795. doi:10.1161/CIRCULATIONAHA.126.079918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。